Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07005128 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

Name: A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC) — clinical trial record (NCT07005128)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: DeLLphi-312

StatusRecruiting

PhasePhase 3

SponsorAmgen

Started2025-08-18

View on ClinicalTrials.gov ↗

The main objective of the study is to compare the efficacy of tarlatamab in combination with durvalumab, carboplatin and etoposide to the combination of durvalumab, carboplatin and etoposide on prolonging overall survival (OS).

Amendment history 4 changes detected by DataLookout

2026-06-26

Trial sites expanded: 158 → 164 locations

2026-05-06

Trial sites expanded: 150 → 153 locations

2026-04-10

Trial sites expanded: 142 → 146 locations

2026-03-31

Trial sites expanded: 131 → 140 locations

Trial Details

NCT Number	NCT07005128
Lead Sponsor	Amgen Collaborators: AstraZeneca
Conditions	Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer
Enrollment	330 participants
Start Date	2025-08-18
Primary Completion	2029-01-04 (estimated)
Study Completion	2029-07-15 (estimated)
Updated on ClinicalTrials.gov	2026-07-16